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Edited by Hans-Dieter KlenkAbstract To clearly demonstrate the role of the human cyto-
megalovirus (HCMV) portal protein pUL104 RNA interference
was applied. Expressing cell lines were constructed by transduc-
tion of shRNAs via the infection with retroviral vectors. After
infection of these cells with HCMV AD169 the expression of
pUL104 was reduced up to 80% for shRNA S1 and 54% for
shRNA S2 at late times of infection compared to controls. In
addition, the inhibitory eﬀect was corresponding with a decrease
in viral mRNA and plaque formations. Electron microscopic
analysis demonstrated that infection of cells expressing
pUL104-speciﬁc shRNAs resulted in the inhibition of formation
of replicative particles.
 2006 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Herpesviruses as well as double-stranded DNA bacterio-
phages express numerous proteins with analog functions in viral
DNA packaging. One of those is the so-called portal protein, in
bacteriophages also known as head-to-tail connector. Large
macromolecular oligomers of portal proteins generate a central
channel at a single vertex of the icosahedral capsid through
whichDNA translocation occurs [2,7,26–28]. All portal proteins
form a dodecameric ring that serves as the gate for DNA entry
and exit out of the capsid [20,39,41]. Although the mechanism of
DNA packaging into the procapsid is still a mystery, this pro-
cess requires an accessory terminase complex, thus providing
ATP hydrolysis [3,13]. The resulting packagingmotor consisting
of the portal ring, the large and the small terminase subunits has
the capacity to package approximately 2 bp of DNA per ATP
[22,35]. A high-resolution structure (610 A˚) of portal proteins
has been determined for dsDNA bacteriophage U29, T7 and
SPP1 [1,20,21,31,34]. Recently, we identiﬁed and characterized
the portal protein of human cytomegalovirus (HCMV),
pUL104 [8,9]. HCMV pUL104 like other known portal proteins
forms high molecular weight multimers.
In order to deﬁne the role of pUL104 for viral replication
RNA interference (RNAi) was performed. In the last couple
of years it has been demonstrated that short interfering RNAs
(siRNAs) are able to silence genes in vivo. These siRNAs
are generated by members of the Dicer family, that cleave*Corresponding author. Fax: +49 30 450 525907.
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25 bp [12,24]. The resulting double-stranded siRNAs are then
incorporated into a silencing complex called RISC which binds
mRNA with a complementary sequence followed by cutting
the homologous region [19,23]. The resulting mRNA is insta-
ble and fragile for degradation, leading to a reduction in
expression of the target gene. Here we used the vector-medi-
ated expression system RNAi-Ready leading to stable delivery
of shRNA to cells. These short hairpin RNAs (shRNAs) were
processed in vivo into siRNA molecules.2. Materials and methods
2.1. Cells and viruses
Human foreskin ﬁbroblasts (HFF) or 293T cells were grown in Dul-
becco‘s minimal essential medium (DMEM) supplemented with 10%
fetal calf serum (FCS), 2 mM glutamine, penicillin (5 U/ml), and strep-
tomycin (50 lg/ml). HFF cells at passages 10–15 were used for infec-
tions and experiments were carried out with conﬂuent cell
monolayers (1.5 · 107 cells). Infection of HFF with HCMV AD169
at a MOI of 3 was carried out as described before [4].
2.2. Plasmid construction
For direct detection of cells containing the gene silcencing construct
eGFP together with an IRES was inserted after the puromycin resis-
tant gene into the vector pSIREN-RetroQ (BD Bioscience Clontech),
yielding pSIREN-RetroQ-eGFP (provided by Frank Neipel). The
RNAi-Ready pSIREN-RetroQ-eGFP vector was used to clone double
stranded oligonucleotides encoding UL104-speciﬁc shRNA. The
shRNA oligonucleotides were designed with 19 bases of sense and anti-
sense strand (Table 1) separated by a hairpin loop (TTCAAGAGA), a
6T terminal sequence followed by the sequence for XhoI restriction
according to the manufacturer (BD Bioscience Clontech). Single
stranded sense and antisense shRNA oligonucleotides were synthesized
(Biomers.net) and both strands were annealed prior to ligation into
pSIREN-RetroQ-eGFP. As a negative control luciferase-speciﬁc
shRNA oligonucleotide was inserted yielding the construct pSIREN-
RetroQ-eGFP si luciferase (provided by Thomas Stamminger).
2.3. Transfection of shRNA expression plasmid
For transient expression 293T cells (5 · 106) were seeded on 10 cm
diameter dishes. 293 T cells at 90% conﬂuency were transfected with
the pSIREN-RetroQ-eGFP, pSIREN-RetroQ-eGFP-shRNA1,
-shRNA2, -shRNA3, and -luciferase together with pcDNA-UL104
[8] by the lipofectamine 2000 method (Invitrogen). As a control
pcDNA-UL104 was co-transfected with pHM829 (expressing eGFP).
The transfection eﬃciency was monitored by GFP ﬂuorescence. Cells
were harvested 40 h post transfection and subjected to Western blot
analysis.
2.4. Western blot
Extracts from mock-infected, infected or transfected cells were sep-
arated on 8% (w/v) polyacrylamide gel and transferred to nitrocellulose
sheets and subjected to Western blot analysis as described previouslyblished by Elsevier B.V. All rights reserved.
Table 1
Oligonucleotides encoding pUL104 target or luciferase sequence
Name Nucleotide sequence Nucleotide
location
shRNA-1 5 0-CGA CGA CTA TGG TCT CTA C-30 503–522
5 0-G TAG AGA CCA TAG TCG TCG-30
shRNA-2 5 0-CGT CTC GGA CAG CAA ATC G-30 1061–1080
5 0-C GAT TTG CTG TCC GAG ACG-30
shRNA-3 5 0-TTA CAC GGT AGA GCG CGT T-30 1709–1726
5 0-A ACG CGC TCT ACC GTG TAA-30
shRNA-lu 5 0-TGC GTT GCT AGT ACC AAC-30 1311–1328
5 0-GTT GGT ACT AGC AAC GCA-30
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as the primary antibody prior to incubation with horseradish peroxi-
dase-conjugated anti-human F(ab 0)2 fragments (1:5000 in 3% BSA).
The membranes were reprobed with an antibody against b-actin
(1:5000) and horseradish peroxidase-conjugated anti-mouse F(ab 0)2
fragments (1:5000) to verify equal loading.
2.5. Lentivirus production and construction of expression cell lines
For construction of retroviral virions the plasmids pHIT60 encoding
for the MLV gag- and pol-proteins (provided by Prof. U¨berla, Univer-
sity Bochum) and pVSV-G encoding the vesicular stomatitis virus G-
protein [6] were used. 4.5 lg of pHIT60, 4.5 lg pVSV-G and 3 lg pSI-
REN-RetroQ-eGFP-shRNA1, -shRNA2, -luciferase or vector alone
were cotransfected into 293T cells (5 · 106 cells). The medium was re-
placed 24 h after transfection with fresh one containing 10% FCS. The
supernatant containing retroviruses was harvested 48 h after transfec-
tion.
HFF cells (8 · 104 cells) were infected with supernatant of retrovi-
ruses to introduce shRNAs of either UL104 shRNA1, shRNA2, luci-
ferase shRNA or the vector alone. The cells were grown in the presence
of puromycin (5 lg/ml). Stable clones were obtained after one week of
selection.
2.6. Plaque reduction assay
Expressing shRNA1, shRNA2, luciferase or vector cell lines were
seeded in 24-well plates and infected with HCMV AD169 with a
MOI of 1 in DMEM. After 1 h of infection the inoculum was replaced
with medium containing 10% FCS and 0.3% agarose. After incubation
for eight days at 37 C the cells were stained with crystal violet and pla-
ques were counted by using a microscope. Eﬀects of the shRNAs were
calculated by comparing shRNA-expressing cells with control wells.
2.7. Preparation of RNA and cDNA
For quantiﬁcation of UL104-mRNA stable shRNA1, shRNA2,
Luciferase or vector expressing HFF cells (1 · 106) were infected with
HCMV at a MOI of 1. Four days post infection cells were harvested
and RNA was extracted. After incubation in 1 ml peqGOLD TriFast
(PEQLAB-Biotechnologie GmbH) for 5 min at RT 200 ll chloroform
were added. Samples were mixed, incubated for 10 min and centrifuged
(12000 · g, 5 min, 4 C). The upper, aqueous phase was removed,
mixed with 500 ll isopropanol and sedimented (12000 · g, 10 min,
4 C). The pellet was washed with 70% ethanol, air-dried, and resus-
pended in 30 ll Aqua bidest. The RNA was immediately used for
cDNA-Synthesis. 20 ll RNA and 2 ll Random Hexamer Primers (Fer-
mentas) were incubated at 80 C for 5 min to dissolve secondary struc-
tures and then immediately placed on ice for at least 2 min. RT
reactions consisted of PCR buﬀer II (PE Biosystems), 3 mM MgCl2,
1 mM dNTPs, 10 mM dithiothreitol, and 40 U MLV reverse transcrip-
tase (Invitrogen) in a ﬁnal volume of 40 ll. The reactions were incu-
bated at 25 C for 5 min and 37 C for 50 min followed by
inactivation at 70 C for 15 min. Final cDNA products were diluted
1:5 in Aqua bidest.
2.8. Real-time quantiﬁcation PCR
Amounts of mRNA of the shRNA-expressing cells were determined
by quantiﬁcation of real-time PCR.
Oligonucleotides for real-time PCR were synthesized by biomers.net
(Ulm, Germany): UL104rtp-fwd 5 0-GCTCGGAGCGGCTGGAGG-CG-3 0/UL104rtp-back 5 0-GCTCGTGGCTGGCGGTC-3 0. Real-time
PCR was performed using 10 ll of cDNA, 0.3 lM ROX-K buﬀer,
1.5 mM MgCl2, 0.5 mM dNTPs, 0.1· SYBR green (Invitrogen),
10 pmol of each primer, 1· Taq PCR buﬀer and Taq DNA polymerase
in a ﬁnal volume of 50 ll. Fifty cycles of ampliﬁcation (94 C for 15 s,
60 C for 30 s, and 72 C for 30 s) were performed in an ABI Prism
7700 spectroﬂuorometric thermal cycler (Applied Biosystems).
DNA standards were ampliﬁed from pcDNA-UL104 with primers
UL104Mi-fwd (GCGAATTCGAGCGGGCGCAATTTGTACGC)
and UL104Mi-back (GCGCGGCCGCGCCGGGCACGAACTGC-
GAGAA). The standards were prepared by serial dilution from 107
to 103 copies per reaction. Standard and cDNA products were tested
in duplicate. The amount of genomic RNA in each probe was also
determined by using primers against actin (provided by K. Metzner,
Erlangen).
2.9. Biostatistical analysis
In order to determine the eﬃciency of the shRNAs on the decrease
in mRNA, plaque formation and Western blot statistical analysis were
performed. The results obtained from paired Student’s t-test were used
to calculate signiﬁcance. A P value of 60.05 was considered signiﬁcant.
2.10. Growth characteristics
HFF cells (8.5 · 104 cells per well) expressing shRNA1, shRNA2,
luciferase or vector were seeded in 24-well culture plates. Conﬂuent
cells were infected with HCMV AD169 at an MOI of 3. At 0, 24,
48, 72, 96 and 120 h p.i. the supernatants were removed from the well
and frozen at 80 C. After collection of all time points the superna-
tants were thawed, transferred to 24-well plates with HFF cells on cov-
er slips and the titers were determined by detection of immediate-early
protein 1 (IE1) expression with indirect immunoﬂuorescence.
2.11. Thin sections
Stable shRNA1, shRNA2, Luciferase or vector expressing HFF cells
were infected with HCMV at a MOI of 1. Four days post infection
cells were ﬁxed with harvesting buﬀer (20 mM HEPES, pH 7.4) con-
taining 4% paraformaldehyde, 2.5% glutaraldehyde and 1% tannin
according to Gelderblom et al. [14]. After dehydration and poststain-
ing with 0.2% (w/v) uranyl acetate the specimen was embedded in gly-
cid ether 100 (Carl Roth) with 1.5% (w/v) 1-methyl-5-norbornene-2,3-
dicarboxylic acid anhydride, methylnadic anhydride (MNA; Carl
Roth). Polymerization was performed at 60 C for several days prior
to sectioning with ultracut S (Reichert-Jung). The sections were trans-
ferred to slot grids coated with pioloform (Plano), stained for 10 min
with 1% (w/v) uranyl acetate in 40% EtOH followed by lead citrate
staining for additional 10 min prior to analysis by electron microscopy.3. Results
3.1. Suppression of pUL104 gene expression
In order to identify the eﬃciency of gene silencing of chosen
shRNA-sequences recombinant pSIREN-RetroQ-eGFP vec-
tors containing either UL104 shRNA1 (pS-sh1), shRNA2
(pS-sh2), shRNA3 (pS-sh3), luciferase shRNA (pS-lu) or the
vector alone (pS-v) were co-transfected with a pUL104 expres-
sion vector (pUL104). In the cells shRNAs were converted into
siRNA-like molecules, initiating RNAi. The expression of
pUL104 was knocked down to 30% in the presence of shRNA1
and shRNA2 against pUL104 (Fig. 1, lanes 5 and 6). In the
presence of the control shRNAs as well as shRNA3 pUL104
expression was identical to cells transfected only with UL104
encoding vector (Fig. 1, lanes 2–4; 7). These observations dem-
onstrated that both shRNAs at least partially silence pUL104
expression.3.2. Reduction mRNA levels in shRNA-expressing cells
To determine the inﬂuence of the eﬀective shRNA1 and
shRNA2 on the amount of mRNA real-time PCR was per-
Fig. 1. Eﬀect of shRNA on expression of pUL104. 293T cells (5 · 106)
were at 90% conﬂuency transfected with pSIREN-RetroQ-eGFP
(pS-v), pSIREN-RetroQ-eGFP-shRNA1 (pS-sh1), -shRNA2 (pS-
sh2), -shRNA3 (pS-sh3) and -luciferase (pS-lu) together with
pcDNA-UL104 by the lipofectamine 2000 method (Invitrogen).
Cells were harvested 40 h post transfection and subjected to Western
blot analysis with the antibody pAbUL104. As a loading control the
immunoblot was consecutively stained with an antibody against actin.
The arrow indicates the positions of pUL104, the molecular weight
markers (M) are shown on the left.
Table 3
Infectious units per ml during infection
shRNA Time post infection (h)
24 48 72 96 120
pS-v 0 720 1450 24000 740000
pS-lu 0 800 1640 26000 885000
pS-sh1 0 120 480 4000 275000
pS-sh2 0 300 470 8000 292500
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with HCMV AD169. After harvesting the cells at 96 h p.i. the
RNA was extracted and used for quantiﬁcation of UL104
mRNA copy numbers. While infection of cells expressing
shRNA1 resulted in a high decrease in UL104 copy numbers,
the eﬀect of shRNA2 was only twofold of UL104 copy numbers
(Table 2). The signiﬁcance of the results was provided by biosta-
tistics analysis by comparison with shRNA luciferase and the
vector control (Table 2). These results showed that both speciﬁc
shRNAs have the ability to reduce the amount of mRNA.
3.3. Inﬂuence of shRNAs on virus yield
Plaque assays were carried out to analyze the ability of sh-
RNAs to reduce virus yield. Both UL104-speciﬁc shRNAs
were able to reduce the plaque formation. While the number
of plaques in the presence of shRNA 1 decreased 70% the
reduction with shRNA 2 was approximately 60% (Table 2).
In cells infected in the presence of shRNA luciferase a reduc-
tion of 30% was observed (Table 2). Cells with the integrated
vector sequence served as control (Table 2). These results
showed that both speciﬁc shRNAs have the ability to reduce
virus yield, but could not inhibit it.
3.4. Reduction of viral growth
In order to analyze the eﬀect of UL104-speciﬁc shRNAs on
viral replication growth curves were performed after infectionTable 2
Eﬀects of shRNAs on UL104-mRNA (copies per ll) and viral replication (p
shRNA Real -time PCR




pS-sh2 2.68 <0.0001/<0of expressing cell lines with HCMV AD169. At 0, 24, 48, 72,
96, 120 h p.i. the supernatants were harvested and transferred
to uninfected HFF. The amount of released virus was mea-
sured by detection of immediate-early protein 1 (IE1) using
immunoﬂuorescence. Both shRNAs had the capacity to reduce
virus release, whereas shRNA1 inhibits virus formation by
approximately 83% while the inhibitory eﬀect of shRNA2
was 67% at 96 h p.i. (Table 3). At 120 h p.i. the reduction of
shRNA1 and 2 were both approximately 60% (Table 3). Taken
together the data presented suggested that the UL104-speciﬁc
shRNAs were able to reduce particle release by over 60%.
3.5. Inhibition of pUL104 expression by shRNAs after infection
To examine whether UL104-speciﬁc shRNA can inhibit
pUL104 expression, stable shRNA 1 (pS-sh1), shRNA2 (pS-
sh2), shRNA-luciferase (pS-lu) or vector (pS-v) expression cell
lines were infected with HCMV AD169 at an MOI of 3 and
Western blot analysis were performed. The amount of detected
pUL104 dimer decreased during infection. At 72 h p.i. the sup-
pression of pUL104 was approximately 35–40% (Fig. 2A and
D), at 96 h p.i. 70% for shRNA1 and 45 for shRNA2
(Fig. 2B and E) and at 120 h p.i. approximately 80% for
shRNA1 and 55% for shRNA2 (Fig. 2C and F). In the pres-
ence of the control shRNA (luciferase) or empty vector no
obvious eﬀect on the pUL104 gene expression was detected.
The signiﬁcance of the results was determined by using paired
Student’s t-time test (Table 4). We could demonstrate that the
eﬀects of the shRNA were sequence speciﬁc, because control
cell lines expressing luciferase shRNA or vector alone showed
no detectable eﬀect.
3.6. Eﬀect of shRNAs on viral maturation
To determine whether the UL104-speciﬁc shRNAs have an
eﬀect on viral maturation electron microscopy of thin section
was performed. Stable expressing cell lines were infected with
HCMV AD169 with an MOI of 3. Five days after infection
the cells were embedded and subjected to sectioning. Three dif-
ferent forms of capsids are formed in the nucleus: B-capsids
containing the scaﬀolding protein (as an electron dense ring),
C-capsids with the packaged DNA and A-capsids representing
abortive products of DNA packaging (empty capsids). Theercentage of vector control)
Plaque-assay





Fig. 2. Suppression of pUL104 in speciﬁc shRNA-expressing cell lines infected by HCMV. ShRNA-expressing shRNA1 (pS-sh1), shRNA2 (pS-sh2),
luciferase (pS-lu) or vector (pS-v) HFF cells (1.5 · 106) were infected with HCMV AD169 at an MOI of 3. At 72 (A), 96 (B) and 120 h p.i. (C) cell
extracts were subjected to 8% SDS–PAGE. The separated probes were transferred onto nitrocellulose prior to immunoblot analysis using the
antibody pAbUL104. As a loading control the immunoblot was consecutively stained with an antibody against actin. Speciﬁcally the detected
proteins were quantiﬁed using bioimaging analysis. The relative amounts of expression are indicated by percent values in the diagram. Error bars on
the histogram are ±S.D. from three independent experiments. The arrows indicate the position of pUL104, the molecular weight markers (M) are
shown on the left.
Table 4
Expression -levels of pUL104 as percentage of vector control
Time p.i. shRNA 72 h 96 h 120 h
% P value pS-v/pS-lu % P value pS-v/pS-lu % P value pS-v/pS-lu
pS-v 100 100 100
pS-lu 88.78 133.58 87.45
pS-sh1 64.10 0.005/0.005 32.45 0.004/0.01 20.68 0.015/ 0.03
pS-sh2 60.93 0.001/0.003 65.35 n.s./n.s. 46.39 n.s./0.027
n.s., not signiﬁcant.
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(NIEPS) arising from A-capsids and virions from C-capsids.
Only NIEPs (Fig. 3B and D) and mainly B-capsids (Fig. 3A
and C) were found in cells expressing shRNA1 and shRNA2.The amount of replicative structures (virions, dense bodies;
Fig. 3F) in the control, shRNAs luciferase expressing cells, is
comparable to wild-type HCMV. The number of C-capsids
versus B-capsids was quantiﬁed and shown in Table 5. These
Fig. 3. Electron microscopy analysis of thin sections of shRNA1 (A,B), shRNA2 (C,D) or luciferase (E,F) expressing cells. After ﬁve days cells were
ﬁxed in 4% paraformaldehyde and 2.5% glutaraldehyde with 1% tannin and prepared for electron microscopy. A, C and E represents an area of the
nucleus while B, D and F one of the cytoplasm. B capsids are indicated by black arrows, A capsids by bold black arrows, C capsids by white arrows,
noninfected particles by black arrows and virions by bold white arrows. db indicates dense bodies. The scale bars correspond to 50 nm.
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block of DNA packaging and therefore in the formation of
replicative particles. This is in line with the assumed function
of pUL104 as a portal protein and demonstrates that
pUL104 is required for DNA-packaging.4. Discussion
For analyzing the function of viral proteins in vivo the con-
struction of deletion mutants is often the method of choice. In
the case of essential gene products this can not be used,
Table 5
Nuclear capsids of infected cells expressing shRNA
shRNA No. of nuclei
counted
No. of capsid form per
nucleus (% )
A B C
pS-sh1 3 10.8 70.4 18.8
pS-sh2 3 18.1 52.5 29.4
pS-lu 3 16.5 38.4 45.3
A. Dittmer, E. Bogner / FEBS Letters 580 (2006) 6132–6138 6137because the virus with the deletion would in almost every case
produce a non-replicating or even lethal phenotype. In the case
of human cytomegalovirus it has been shown by random
mutagenesis of the genome that 41 open reading frames includ-
ing UL104 are essential for viral replication [10,11]. A new
promising approach is the use of siRNAs that allow the anal-
ysis of the gene function [24,25]. In this study, we used plas-
mid-based UL104-speciﬁc short hairpin (sh) RNAs as
speciﬁc inducers of RNA silencing [5,36,37,42]. This system al-
lows a continuous intracellular synthesis of shRNAs resulting
in constant siRNAs levels over a long period of time. The sh-
RNAs were synthesized in HFF cells which were stable trans-
fected with the U6-expression vector pSIREN-RetroQ-eGFP.
Infection of stable shRNA-expressing HFF with HCMV
AD169 leads to the suppression of pUL104. This eﬀect in-
creased during time of infection, whereas after ﬁve days the
maximum reduction of more than 40% for shRNA2 and even
a remarkable reduction in pUL104 expression of 89% for
shRNA1 were observed. We could demonstrate that the eﬀects
of the shRNA were sequence speciﬁc, because control cell lines
expressing luciferase shRNA or vector alone showed no detect-
able eﬀect. Interestingly, the shRNA-mediated block of
pUL104 aﬀects the release of virus both in plaque reduction
and in virus yield assays up to threefold as well as a decrease
in the amount of mRNA of up to fourfold.
Since a phenotype can be observed by using shRNA-medi-
ated gene knockdown we performed electron microscopy anal-
ysis of the shRNA-stable expressing cells. While in the infected
cells expressing shRNA 1 almost no replicative particles could
be observed, in shRNA 2 cells some cytoplasmic virions were
detected. However, the amount of replicative particles in the
control, shRNA luciferase expressing cells, is comparable to
wild-type HCMV. Thus demonstrated that UL104-speciﬁc
RNAi resulted in a block of DNA packaging and therefore
in the formation of replicative particles.
Furthermore, previous investigators have shown for HSV-1
and the dsDNA bacteriophages U29 and P22 that in contrast
to other bacteriophages capsid formation can take place in
the absence of a portal protein both in vitro/in vivo
[29,30,32–34,38,40]. Given that the overall number of capsids
in both UL104 and luciferase speciﬁc shRNA expressing cells
is similar, it can be speculated that this is also the case for
HCMV. Since there is no in vitro assembly system for the
HCMV capsid, RNAi may provide a tool to study the eﬀects
that the lack of single components has on capsid formation
and the packaging process.
Recently, Godfrey et al. [18] demonstrated that primary eﬀu-
sion lymphoma can be inhibited by lentiviral vectors encoding
shRNA of the oncogenic cluster of KSHV in vitro/in vivo in a
mice model. The usage of lentiviral-based vectors with incor-
porated sequence-speciﬁc shRNA enable the eﬃcient targeting
of RNA in vivo. However, it has been reported that extensivetreatment of enterovirus with RNAi leads to the development
of escape mutants [16,17]. The authors have shown that it
might be prevented by targeting multiple gene products [17].
Our observations lead us to the hypothesis that lentivirus-
delivered RNAi can be used as a potential therapy against
HCMV.
In conclusion, expression of UL104-speciﬁc hairpin shRNAs
(i) can silence the target gene and (ii) furthermore inhibit the
formation of replicative particles conﬁrming the role of
pUL104 in viral DNA packaging. Given the need of new anti-
viral therapies, especially regarding the cross-resistances of the
current available compounds, the use of vector-mediated
shRNA as an antiviral strategy for HCMV has a great poten-
tial.
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